Journal
DERMATOLOGIC THERAPY
Volume 34, Issue 1, Pages -Publisher
WILEY
DOI: 10.1111/dth.14461
Keywords
adverse effects of oncologic drugs; drug‐ induced sweet syndrome; neutrophilic dermatosis; sweet syndrome; targeted anticancer therapy; tyrosine kinase inhibitor
Categories
Ask authors/readers for more resources
Tyrosine kinase inhibitors are targeted anticancer drugs that inhibit cancer cell proliferation by inactivating proteins involved in signal transduction cascades. Skin adverse events, including Sweet syndrome, can occur after treatment with these inhibitors. A study identified 14 cases of tyrosine kinase inhibitor-induced Sweet syndrome with a median latency period of 2 months, most showing classic clinical and histopathologic features. Treatment approaches varied, with some cases resolving with corticosteroids while others required medication discontinuation.
Tyrosine kinase inhibitors are a class of targeted anticancer drugs that inhibit cancer cell proliferation by inactivating proteins involved in signal transduction cascades. Various cutaneous adverse events have been observed after tyrosine kinase inhibitor administration, including Sweet syndrome. We queried the PubMed database to identify 14 cases of Sweet syndrome thought to be secondary to tyrosine kinase inhibitors. Tyrosine kinase inhibitor-induced Sweet syndrome had a median of 2 months latency following drug administration. All cases but one had morphologic features classic for Sweet syndrome (erythematous and tender papules, plaques, or nodules). All cases also had classic histopathologic findings (dermal neutrophilic infiltrate without vasculitis or necrosis). Using diagnostic criteria for drug-induced Sweet syndrome and the Naranjo Drug Reaction Probability Scale for a drug-induced cutaneous eruption, we found that six cases favored a drug-induced etiology over malignancy, two cases favored a malignancy-associated Sweet syndrome, and the remaining eight met drug-induced Sweet syndrome criteria but had low Naranjo scores. Nine cases resulted in medication discontinuation, while five cases continued anticancer therapy and were treated only with corticosteroids with quick resolution of skin lesions. Dermatologists should be aware of this adverse cutaneous reaction to tyrosine kinase inhibitors and should treat on a case-by-case basis, though limited evidence in this review suggests that oncologic therapy may safely be continued with prompt corticosteroid treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available